{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:57:10Z","timestamp":1790906230553,"version":"4.1.0"},"reference-count":18,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            To prevent complications that might follow an infection with varicella-zoster virus (VZV), the live attenuated Oka strain (V-Oka) is administered to children in many developed countries. Three vaccine brands (Varivax from Sanofi Pasteur MSD; Varilrix and Priorix-Tetra, both from Glaxo-Smith-Kline) are licensed in Germany and have been associated with both different degrees of vaccine effectiveness and adverse effects. To identify genetic variants in the vaccines that might contribute to rash-associated syndromes, single nucleotide polymorphism (SNP) profiles of variants from the three vaccines and rash-associated vaccine-type VZV from German vaccinees were quantitatively compared by PCR-based pyrosequencing (PSQ). The Varivax vaccine contained an estimated 3-fold higher diversity of VZV variants, with 20% more wild-type (wt) SNPs than Varilrix and Priorix-Tetra. These minor VZV variants in the vaccines were identified by analyzing cloned full-length open reading frame (ORF)\n            <jats:italic>orf62<\/jats:italic>\n            sequences by chain termination sequencing and PSQ. Some of these sequences amplified from vaccine VZV were very similar or identical to those of the rash-associated vaccine-type VZV from vaccinees and were almost exclusively detected in Varivax. Therefore, minorities of rash-associated VZV variants are present in varicella vaccine formulations, and it can be concluded that the analysis of a core set of four SNPs is required as a minimum for a firm diagnostic differentiation of vaccine-type VZV from wt VZV.\n          <\/jats:p>","DOI":"10.1128\/cvi.05021-11","type":"journal-article","created":{"date-parts":[[2011,5,12]],"date-time":"2011-05-12T01:17:48Z","timestamp":1305163068000},"page":"1058-1066","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":26,"title":["Molecular Analysis of Varicella Vaccines and Varicella-Zoster Virus from Vaccine-Related Skin Lesions"],"prefix":"10.1128","volume":"18","author":[{"given":"Sonja","family":"Thiele","sequence":"first","affiliation":[{"name":"Division of Viral Infections, Robert Koch Institute, D-13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aljona","family":"Borschewski","sequence":"additional","affiliation":[{"name":"Division of Viral Infections, Robert Koch Institute, D-13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"K\u00fcchler","sequence":"additional","affiliation":[{"name":"Division of Viral Infections, Robert Koch Institute, D-13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bieberbach","sequence":"additional","affiliation":[{"name":"Division of Viral Infections, Robert Koch Institute, D-13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Voigt","sequence":"additional","affiliation":[{"name":"Division of Viral Infections, Robert Koch Institute, D-13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Ehlers","sequence":"additional","affiliation":[{"name":"Division of Viral Infections, Robert Koch Institute, D-13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/522140"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00526-07"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-67-9-1759"},{"key":"e_1_3_3_5_2","first-page":"49","article-title":"Comparison of DNA sequence and transactivation activity of open reading frame 62 of Oka varicella vaccine and its parental viruses","volume":"2001","author":"Gomi Y.","year":"2001","unstructured":"GomiY. ImagawaT. TakahashiM. YamanishiK.. 2001. Comparison of DNA sequence and transactivation activity of open reading frame 62 of Oka varicella vaccine and its parental viruses. Arch. Virol. Suppl. 2001:49\u201356.","journal-title":"Arch. Virol. Suppl."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1096-9071(200008)61:4<497::AID-JMV13>3.0.CO;2-2"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.069"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.22.11447-11459.2002"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21506"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/510532"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0605688104"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/423210"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1101\/gr.11.1.3"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.12.5604-5608.2004"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2006.07.002"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00802-10"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.15.13.19530-en"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.10.086"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00777-08"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.05021-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.05021-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T21:20:46Z","timestamp":1630963246000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.05021-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.1128\/CVI.05021-11"],"URL":"https:\/\/doi.org\/10.1128\/cvi.05021-11","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7]]},"assertion":[{"value":"2011-03-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-05-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-07-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}